source
- Daraxonrasib doubles median survival in pancreatic cancer trial, FDA grants early accessAn international study presented at the American Society of Clinical Oncology meeting in Chicago showed that patients with pancreatic cancer who received daraxonrasib lived an average of 13.2 month…
- Tennessee pharmacies sell high-strength ivermectin under anti-vaccine doctor's directionTennessee pharmacies have begun offering high-strength formulations of the antiparasitic drug ivermectin. The sales are being led by a physician known for anti-vaccine views, who has publicly said…